TEPEZZA
Q2 2026 sales rose 14% to $576 million; a subcutaneous Phase 3 study is due to finish in H2 2026.
The numbers
TEPEZZA product sales$576 millionQ2 2026 · up 14% year over year · source ↗
What it is
Treatment for thyroid eye disease, an autoimmune eye condition. Amgen is testing a subcutaneous form to widen its use.
Why it matters to the stock. TEPEZZA is one of Amgen's few specialty products with double-digit growth. A subcutaneous version could widen its patient base.
News
Subcutaneous TEPEZZA meets primary endpoint in Phase 3 thyroid eye disease study
Amgen reported positive topline Phase 3 results for a subcutaneous on-body injector version of TEPEZZA in adults with moderate-to-severe active thyroid eye disease.
Project